Showing 4051-4060 of 5957 results for "".
- Study: Pediatric Keratoconus Prevalence Higher than Believed; May Change Care Approachhttps://modernod.com/news/study-pediatric-keratoconus-prevalence-higher-than-believed-may-change-care-approach/2482171/A new study, published in the journal Eye and Contact Lens, found that by utilizing Scheimpflug tomography during a comprehensive eye examination clinicians identified keratoconus in a limited pediatric population at a far gre
- Industry Opticianry Organizations Announce Merger at Vision Expo Easthttps://modernod.com/news/industry-opticianry-organizations-announce-merger-at-vision-expo-east/2482169/The Opticians Association of America [OAA], and the National Federation of Opticianry Schools [NFOS], have completed a merger to create the "United Opticians Association [UOA]," a model Opticianry Association representing over 80,000 opticians and contact lens professionals throughout N
- NewSight Reality Unveils Transparent Optical Module (TOM) 2.0 at Vision Expo East 2024https://modernod.com/news/newsight-reality-unveils-transparent-optical-module-tom-20-at-vision-expo-east-2024/2482167/NewSight Reality (NSR), a provider of Augmented Reality (AR) technologies, announced the next generation of its Transparent Optical Module (TOM) 2.0 at the Vision Expo East meeting. Highlights of the new technology include a patented stray light shielding solution, active micro-len
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- Apellis Appoints Philip Ferrone, MD, as Chief Medical Retina Advisorhttps://modernod.com/news/apellis-appoints-philip-ferrone-md-as-chief-medical-retina-advisor/2482154/Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, MD, will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Reti
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- AcrySof IQ Vivity and Clareon Vivity EDOF IOLs Reach 1 Million Implants Milestonehttps://modernod.com/news/acrysof-iq-vivity-and-clareon-vivity-edof-iols-reach-1-million-implants-milestone/2482147/Alcon announced that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) IOLs have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally, according to Alcon.[1] “We are proud to celebrate